Observed Signal · Oct 29, 2026 · Earnings Report · Source: PR Newswire: Technology News · Impact: 1/5 · Sentiment: Positive
Penumbra Q3 2026 Results Strong, Acquisition Pending
Penumbra, a thrombectomy company, reported strong Q3 2026 results with revenue of $410.1M, up 15.6% year-over-year. Global thrombectomy revenue grew 18.1% to $279.2M, while embolization and access revenue rose 10.8%. Net income was $42.3M. The company highlighted a pending acquisition by Boston Scientific Corporation, which incurred $7.1M in acquisition-related expenses. Due to the pending deal, Penumbra will not provide full-year guidance or host a conference call. The acquisition is subject to regulatory approvals and other conditions.
Relevant to AdTech/MarTech only as a potential data point for health advertising, but primarily a medical device earnings report unrelated to marketing technology.
Track Real-Time Financials Signals & Market Shifts
Polaris7 autonomous intelligence agents track regulatory filings, primary sources, executive changes, and deal flow 24/7. Create your Polaris7 workspace to monitor these entities.
Key Takeaways & Evidence Grounding
- Revenue increased 15.6% to $410.1M in Q3 2026.
- Global thrombectomy revenue grew 18.1% to $279.2M.
- Gross profit margin improved to 68.3%.
- Net income was $42.3M.
- Pending acquisition by Boston Scientific Corporation.
Related Market Signals & Shifts
Recent verified developments and strategic activity across this market segment.
Accuray Reports Fiscal Q1 Results, Transformations Progress
Accuray Incorporated reported financial results for the first quarter of fiscal 2027, ended September 30, 2026. Total net revenue decreased 8% year-over-year to $86.5 million, with product revenue down 26% but service revenue up 4%. The company recorded a net income of $10.1 million, including a $59.6 million non-cash gain on debt extinguishment and a $35.4 million goodwill impairment charge. Excluding these items, net loss improved to $14.0 million from $21.7 million a year ago. Adjusted EBITDA turned positive at $2.5 million. Accuray also signed a definitive agreement with RaySearch to advance online adaptive radiation therapy, and progressed a collaboration with Samsung NeuroLogica on volumetric imaging. The company's financing transaction with TCW, including a $40 million debt-for-equity exchange, is pending stockholder approval.
10-Q Financial Filing Analysis for Medtronic (2026-09-03)
Medtronic plc reported net sales of $9.756 billion for Q1 FY2027 (ended July 31, 2026), marking a 14% year-over-year increase supported by broad segment growth and an additional fiscal week. The company actively expanded its neuroscience portfolio through strategic acquisitions of Scientia Vascular ($681 million) and SPR Therapeutics ($654 million). Additionally, Medtronic advanced the full divestiture of its remaining stake in MiniMed Group following its March 2026 IPO, and executed post-quarter strategic transactions including a $700 million investment in Cornerstone Robotics and a $1.0 billion cross-currency swap. However, the company faces material legal headwinds, actively contesting a $382 million antitrust verdict (subject to trebling) and an $88 million product liability award.
Sera Prognostics Reports Q3 2026 Results
Sera Prognostics, a diagnostics company focused on pregnancy health, reported third-quarter 2026 financial results. PreTRM test volume increased 54% sequentially, and revenue reached $42,000, a 163% year-over-year increase. The company's net loss was $8.05 million for the quarter. Florida became the second state to provide Medicaid coverage for the PreTRM test, expanding to approximately 7 million covered lives. The company also initiated CE Mark submission for its PreTRM Global test in Europe and expanded its sales team by 25%.
Receive all future signals for Financials in your executive briefing
Never miss material M&A deals, leadership changes, account wins, or product rollouts. Polaris7 monitors 20,000+ primary sources 24/7, delivering verified telemetry directly into your executive briefing.